The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review

Guévelou, Jennifer Le; Sargos, P.; Ploussard, Guillaume; Ost, Piet; Gillessen, Silke; Zilli, Thomas

doi:10.1016/j.euf.2022.08.016

Cited by 11 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it is worth noting that the treatment also resulted in a high rate of grade 3/4 adverse events (AEs), with nearly 80% of participants experiencing these severe AEs ( 8 ). Despite significant improvements in systemic therapies for ccRCC, only a few patients have achieved a durable clinical response, with the median PFS ranging from 11.6 to 15.4 months, even with first-line treatment ( 9 ) followed by the therapy-resistance. Additional therapeutic strategies to improve the efficacy of systemic therapies are therefore urgently needed, especially in patients with limited disease burden.…”

Section: Introductionmentioning

confidence: 99%

Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab

et al. 2023

View full text Add to dashboard Cite

BackgroundManagement of clear cell renal cell carcinoma (ccRCC) has changed rapidly in recent years with the advent of immune checkpoint inhibitors (ICIs). However, only a limited number of patients can sustainably respond to immune checkpoint inhibitors and many patients develop resistance to therapy, creating an additional need for therapeutic strategies to improve the efficacy of systemic therapies.MethodsBinding probability and target genes prediction using online databases, invasion, migration, and apoptosis assays as well as the inhibition of cancer stem cells (CSCs) markers in ccRCC cell lines were used to select the most promising phytochemicals (PTCs). Mixed lymphocyte tumor cell culture (MLTC) system and flow cytometry were performed to confirm the potential combination strategy. The potential immunotherapeutic targets and novel CSC markers were identified via the NanoString analysis. The mRNA and protein expression, immune signatures as well as survival characteristics of the marker in ccRCC were analyzed via bioinformation analysis.ResultsShikonin was selected as the most promising beneficial combination partner among 11 PTCs for ipilimumab for the treatment of ccRCC patients due to its strong inhibitory effect on CSCs, the significant reduction of FoxP3+ Treg cells in peripheral blood mononuclear cells (PBMCs) of patients and activation of the endogenous effector CD3+CD8+ and CD3+CD4+ T cells in response to the recognition of tumor specific antigens. Based on NanoString analysis VCAM1, CXCL1 and IL8 were explored as potential immunotherapeutic targets and novel CSC markers in ccRCC. The expression of VCAM1 was higher in the tumor tissue both at mRNA and protein levels in ccRCC compared with normal tissue, and was significantly positively correlated with immune signatures and survival characteristics in ccRCC patients.ConclusionWe propose that a combination of shikonin and ipilimumab could be a promising treatment strategy and VCAM1 a novel immunotherapeutic target for the treatment of ccRCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab

et al. 2023

View full text Add to dashboard Cite

show abstract

“… 5 , 44 Metastasis-directed therapies are associated with low toxicity rates and excellent local control (> 90%), which extend patients’ time on their current systemic treatment by approximately 9 months, and lead to improved progression-free survival ranging from 8 to 15 months. 45 A single-arm feasibility trial found that patients with low-volume disease (≤ 5 metastatic lesions) treated with SBRT to all metastatic sites had a progression-free survival of 22.7 months, 46 and 82% of patients were alive and not on systemic therapy at 1 year. Clinical trials are ongoing to determine whether there is an overall survival benefit.…”

Section: How Should Patients With Metastatic Disease Be Managed?mentioning

confidence: 99%

Advances in the management of renal cell carcinoma

Cardenas,

Sigurdson,

Wallis

et al. 2024

CMAJ

View full text Add to dashboard Cite

“…Les traitements définitifs ciblant les métastases, qui comprennent la résection chirurgicale ou la RSA à tous les sites de la maladie, sont recommandés pour les personnes atteintes d’une maladie oligométastatique 5 , 44 . Les traitements ciblant les métastases sont associés à de faibles taux d’effets toxiques et à un excellent contrôle local (> 90 %), qui allonge la durée du traitement systémique actuel d’environ 9 mois et entraîne une meilleure survie sans progression, qui va de 8 à 15 mois 45 . Une étude de faisabilité à 1 seul groupe a révélé que les personnes présentant une maladie peu volumineuse (≤ 5 lésions métastatiques) traitées par RSA à tous les sites métastatiques avaient une survie sans progression de 22,7 mois 46 , et 82 % des patients étaient toujours vivants et ne recevaient aucun traitement systémique à 1 an.…”

Section: Comment Prendre En Charge Les Personnes Présentant Une Malad...unclassified

Percées dans la prise en charge de l’hypernéphrome

Cardenas,

Sigurdson,

Wallis

et al. 2024

CMAJ

View full text Add to dashboard Cite

The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review

Cited by 11 publications

References 49 publications

Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab

Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab

Advances in the management of renal cell carcinoma

Percées dans la prise en charge de l’hypernéphrome

Contact Info

Product

Resources

About